They collected skin biopsies from patients with diffuse cutaneous SSc (dcSSc) in the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial who underwent autologous hematopoietic ...

Not all patients with deterioration in pulmonary function tests have a progressive disease: 30% of patients develop progressive lung disease and only 16% will develop severe lung fibrosis (defined ...

SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...

Autoimmune bullous diseases are often associated with significant morbidity and some can even cause mortality, if left untreated. Multiple therapies are now available to treat these blistering ...

The ACR has released a summary of a new 2024 guideline for the screening, treatment, and management of Lupus Nephritis.

The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in ...

Chemotherapy often causes hair loss, but it can depend on the type of chemo drug and other factors. An estimated 65% of people undergoing classic chemotherapy experience hair loss, or what doctors ...

Studies include the Phase III SUNMO trial evaluating the efficacy and safety of subcutaneously administered Lunsumio ® (mosunetuzumab-axgb) in combination with intravenous (IV) Polivy versus IV ...

Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a ...

Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems1 These encouraging five-year results ...

About 20% of patients with stage II, III, and IV follicular lymphoma will relapse within two years of front-line therapy ... Often, chemotherapy is given in a regimen of four drugs known as CHOP ...